TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04389892

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced harmonic endoscopic ultrasound
Description: During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications
Study: NCT01683409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT04218084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: Participants are randomized 1:1 to receive voxelotor or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study: NCT01506167

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab was administered as part of standard first-line treatment

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab was administered as part of standard first-line treatment

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab was administered as part of standard first-line treatment

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab was administered as part of standard first-line treatment

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab was administered as part of standard first-line treatment

Intervention type: DRUG
Intervention: Capecitabine/Oxaliplatin
Description: Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment

Intervention type: DRUG
Intervention: Fluorouracil/Folinic Acid/Oxaliplatin
Description: Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine was administered along with bevacizumab as part of standard first-line treatment

Intervention type: DRUG
Intervention: Fluorouracil/Folinic Acid/Irinotecan
Description: Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment

Intervention type: DRUG
Intervention: Fluorouracil +/- Folinic Acid
Description: Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
Study: NCT01868750

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: 1.0ug twice daily for 7 days before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Pill
Description: placebo pill taken twice daily for 7 days before surgery
Study: NCT02632955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon
Description: After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Regular angioplasty
Description: After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
Study: NCT00144963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposomes Injection
Description: Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
Study: NCT02536040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% diammine silver fluoride
Description: treatment of cavity with study agent

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Fluoride free, distilled water
Study: NCT01683409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01860079

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early discharge
Description: In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
Study: NCT03766009

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Description: Web-based decision aid received prior to the surgical consultation
Study: NCT02684630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System
Description: Platelet Apheresis Procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System
Description: Platelet Apheresis Procedure
Study: NCT02699060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy with biopsy and collection of refluxate
Description: we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy with biopsy and collection of refluxate
Description: we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy with biopsy and collection of refluxate
Description: we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring
Description: we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring
Description: we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring
Description: we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
Study: NCT00770081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: 50mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: 25mg qd
Study: NCT01279083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-112
Description: Topical ocular solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-112
Description: Topical ocular solution
Study: NCT03742102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
Study: NCT01279083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-112
Description: Topical ocular solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-112
Description: Topical ocular solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-112 Vehicle Solution
Description: Topical ocular solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Solution
Description: Topical ocular solution
Study: NCT02283008

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of inhaler technique pre and 6 weeks post training
Description: Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
Study: NCT03813953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: Resection of diseased liver

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: Resection of diseased liver
Study: NCT01758588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 50 mcg subcutaneous injection once per week
Study: NCT00767624

Intervention type: DRUG
Group type: OTHER
Intervention: Antidepressant
Description: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance

Intervention type: DRUG
Group type: OTHER
Intervention: Antidepressant
Description: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Desensitization Therapy for Insomnia

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia
Study: NCT02826538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fracture fixation with patient specific guides
Description: Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard procedure of fracture fixation
Description: the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
Study: NCT01734200

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriobotyra Japonica Lindley Extract
Description: Eriobotyra Japonica Lindley Extract (1.5g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1.5g/day)
Study: NCT00381160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of sugar-sweetened beverage consumption
Description: Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
Study: NCT03632525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin \<14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).
Study: NCT04790708

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-treatment 90Y-DOTATOC
Description: 3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-treatment 90Y-DOTATOC
Description: 3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-treatment 90Y-DOTATOC
Description: 3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-treatment 90Y-DOTATOC
Description: 3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-treatment 90Y-DOTATOC
Description: 3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-treatment 90Y-DOTATOC
Description: 3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
Study: NCT04482673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily Vitamin D3
Description: 6000 IU vitamin D3 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily Vitamin D3
Description: 6000 IU vitamin D3 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily placebo
Description: Placebo daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily placebo
Description: Placebo daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus vitamin D3
Description: Bolus 20,000 IU vitamin D3 daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bolus placebo
Description: Bolus placebo daily for 3 days
Study: NCT02769962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0057
Description: EP0057 IV Q 2weeks Day 1 and Day 15, administered in 28 day cycles, until disease progression or development of intolerable side effects~Plus olaparib (PO days 3-13\* and days 17-26\*) administered in 28 day cycles, until disease progression or development of intolerable side effects. P1: Dose Escalation P2: RP2D~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)
Study: NCT04298892

Intervention type: OTHER
Intervention: clinical data and sample collection
Description: Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
Study: NCT01366690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
Study: NCT03742102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Study: NCT03278782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study: NCT02145832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Study: NCT02769962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0057
Description: EP0057 IV Q 2weeks Day 1 and Day 15, administered in 28 day cycles, until disease progression or development of intolerable side effects~Plus olaparib (PO days 3-13\* and days 17-26\*) administered in 28 day cycles, until disease progression or development of intolerable side effects. P1: Dose Escalation P2: RP2D~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: olaparib (PO days 3-13\* and days 17-26\* administered in 28 day cycles, until disease progression or development of intolerable side effects Plus EP0057 (IV Q 2weeks, Day 1 and Day 15) administered in 28 day cycles, until disease progression or development of intolerable side effects P1: Dose Escalation P2: RP2D (\* On days 13 and 26, only one dose of olaparib will be administered in the morning)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: olaparib (PO days 3-13\* and days 17-26\* administered in 28 day cycles, until disease progression or development of intolerable side effects Plus EP0057 (IV Q 2weeks, Day 1 and Day 15) administered in 28 day cycles, until disease progression or development of intolerable side effects P1: Dose Escalation P2: RP2D (\* On days 13 and 26, only one dose of olaparib will be administered in the morning)
Study: NCT01326650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: daily oral vitamin D supplement of 100 micrograms for three years
Study: NCT02145832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Study: NCT01326650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily oral placebo supplement for three years
Study: NCT03909880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio tape
Description: Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping.
Study: NCT01446328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Tablets, dose range 50-1200 mg/ day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, dose range 5-30 mg/ day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Tablets, dose range 2.5-20 mg/ day
Study: NCT01767948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
Study: NCT04634682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MYODM
Description: Formulated composition containing Theobroma cacao supplemented with caffeine
Study: NCT01088841

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactisole
Description: lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
Study: NCT01767948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.